Business Context and Reporting Period
This Form 8-K Current Report was filed by Accuray Incorporated on June 9, 2011. The report addresses the approval of a previously announced merger agreement entered into on March 6, 2011, between Accuray, TomoTherapy Incorporated, and Jaguar Acquisition, Inc. (Merger Sub). On the reporting date, TomoTherapy shareholders voted to approve the merger, under which TomoTherapy will become a wholly-owned subsidiary of Accuray.
Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for Accuray or TomoTherapy. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the successful shareholder vote by TomoTherapy to adopt the Merger Agreement. This action advances the transaction toward closing, subject to the satisfaction of remaining closing conditions.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the expected structure and timetable of the transaction. Management cautions that actual results may differ materially due to several risks, including:
- The satisfaction of closing conditions for the transaction.
- Market conditions and general industry economic factors.
- The effect of the announcement on the respective businesses of Accuray and TomoTherapy.
- The risk of failure to complete the transaction or realize anticipated benefits.
- Potential inability to successfully integrate TomoTherapy's business operations.
Investors are directed to the Risk Factors sections of Accuray's Form 10-Q (ended March 31, 2011), TomoTherapy's Form 10-K (ended December 31, 2010) and Form 10-Q (ended March 31, 2011), and Accuray's Registration Statement on Form S-4 for a comprehensive list of risks.
Key Facts for Investor Verification
- Confirm the specific closing conditions required to finalize the merger between Accuray and TomoTherapy.
- Review the definitive proxy statement/prospectus filed on May 9, 2011, for detailed transaction terms and financial implications.
- Monitor the integration plan and potential operational synergies between the two medical device companies.
- Verify the status of regulatory approvals required for the transaction to close.